{"analyses":[{"ciLowerLimit":"0.477","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.805","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.0003","paramType":"Hazard Ratio (HR)","paramValue":"0.619","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.9","upperLimit":"19.8","value":"18.0"},{"groupId":"OG001","lowerLimit":"9.7","upperLimit":"12.3","value":"11.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"168"}],"units":"Participants"}],"description":"DoR was defined as the date of first documented CR or PR (responder) to the date of progressive disease or the date of death due to any cause, whichever was earlier. If a responder was not known to have died or have progressive disease, then the participant was censored at the date of last evaluable tumor assessment.CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \\<10 mm, and normalization of tumor marker levels of non-target lesions. PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Part B: Ramucirumab+ Erlotinib"},{"description":"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","id":"OG001","title":"Part B: Placebo+ Erlotinib"}],"paramType":"MEDIAN","populationDescription":"Part B: All randomized participants grouped according to their assigned treatment at randomization that had a response (CR or PR). Per protocol, Part A did not evaluate efficacy.","reportingStatus":"POSTED","timeFrame":"Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up To 37 Months)","title":"Part B: Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"months"}